TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change in perception of work group and leader
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in nurse satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Percent denervation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Satisfaction with medical care system
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Arm problems
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain scores exceeding 3/10
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in SPPB score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AF detection rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: IL-6 levels at 24 hours after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: λ values for Gd-BOPTA compared to Gd-DTPA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: T1 times of myocardium and blood pool
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: individual mobility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biochemical failure (BCF) probability
Endpoint domain: Mortality/survival
Primary endpoint: increase in minimal lumen diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: reduction in diameter stenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: increase in percent stent expansion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidences of nausea, vomiting and itching
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of placental abruption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Total area under the plasma zolpidem concentration-time curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak plasma concentration of zolpidem
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BMI variation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Gestational diabetes mellitus diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Delayed maximal inhibition of platelet aggregation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Reduced area under the curve levels of clopidogrel active metabolite
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Higher residual platelet aggregation after morphine injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: mRNA levels of genes involved in ATP production and mitochondrial biogenesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: RV tissue displacement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: peak systolic strain rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: PASI 75 responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Foot form improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fall prevention
Endpoint domain: Adverse events/effects
Primary endpoint: Detection rate of NMIBC and carcinoma in situ
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Reduction of residual tumor rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: ACPR at D28
Endpoint domain: Mortality/survival
Primary endpoint: IgE antibodies levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: IgG antibodies levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Range of motion for cervical rotation and lateral flexion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean number of stools per day
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Recalled reports accuracy for lower urinary tract symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Proportion of patients who wanted to complete an advance directive and took one home
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Post-test performance
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Response to initial sertraline therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reaction time to identify facial expressions of sadness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cardiac event rate
Endpoint domain: Mortality/survival
Primary endpoint: stent vessel occlusion
Endpoint domain: Adverse events/effects
Primary endpoint: intention to purchase combustible cigarettes
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: intention to purchase Absolute e‐cigarettes
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: NPZ‐7 score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: proportion with symptomatic neurocognitive impairment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Odds of having Metabolic Syndrome (MetS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Circulating levels of High sensitivity C‐Reactive Protein (hsCRP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Circulating levels of Leptin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: median viral load (VL) change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fatigue associated with surgery
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Recognition of sad facial expressions
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Gonorrhea incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Consistent refusals of unprotected sex
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Ease of understanding of line graphs
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Usefulness of line graphs
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Average cost of treatment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: total insulin dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: dose-intensity maintenance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of death within 3 weeks of starting chemotherapy
Endpoint domain: Mortality/survival
Primary endpoint: Rash grade improvement
Endpoint domain: Adverse events/effects
Primary endpoint: median effective analgesic dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Days taken to resume normal activities
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Blood lactic acid levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: volume fraction of mesangial matrix per glomerulus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: incidence of severe hypoglycemic episodes
Endpoint domain: Adverse events/effects
Primary endpoint: Change in percentage of glycated haemoglobin (HbA1c%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Perceptual and cognitive performance
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: slow gait speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mortality rates after lung volume reduction surgery
Endpoint domain: Mortality/survival
Primary endpoint: Improvement in alexithymia severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ability to fall asleep
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: effective pain relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: C‐NRS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of hypochromic microcytic anemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: BMI z‐score change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HIV transmission rate
Endpoint domain: Mortality/survival
Primary endpoint: Mean treatment group difference in BMI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of shoulder pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall pain score at the time of first analgesic request
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: composite of stroke, myocardial infarction, or vascular death
Endpoint domain: Mortality/survival
Primary endpoint: ischaemic stroke within 90 days
Endpoint domain: Mortality/survival
Primary endpoint: Time to attain full enteral feedings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: motor-evoked potential (MEP) amplitudes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: short intracortical inhibition (SICI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: goal performance (COPM)
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Cumulative incidence of refractory leukemia or recurrence (CIR)
Endpoint domain: Mortality/survival
Primary endpoint: Number of illnesses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean distance from buccal bone to lingual bone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Healing of circumferential defects without guided bone regeneration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of bone remodeling around immediate or delayed implants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of withdrawals
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of days on treatment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Risk ratio of death
Endpoint domain: Mortality/survival
Primary endpoint: Trainee satisfaction with education
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Faculty satisfaction with education
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean 24-h urine protein reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Serum potassium levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Time in target glucose range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Delayed image H/M ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Norepinephrine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Freedom from angina, reinterventions and combined cardiac events
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of AO
Endpoint domain: Mortality/survival
Primary endpoint: Reduction of fear of childbirth
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Decision on mode of delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Reduction of elective cesarean section
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: days of cannabis use during the past month
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: past-month quantity of cannabis use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: symptoms of cannabis abuse
Endpoint domain: Adverse events/effects
Primary endpoint: Na(+)K(+)ATPase activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of embolic events
Endpoint domain: Mortality/survival
Primary endpoint: Reinfarction risk
Endpoint domain: Mortality/survival
Primary endpoint: Frontal plane balance test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: risk of developing new carious lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Dental outcomes
Primary endpoint: sAA reactivity to substance-infusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: β‐endorphin increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ACTH increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AIDS or death
Endpoint domain: Mortality/survival
Primary endpoint: Time to onset of complete sensory and motor block
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of skin to glucocorticoid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Incidence and duration of grade 3 and 4 neutropenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Time to hematologic recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Adoption and use of improved cookstoves
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: amount of pethidine requirement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to walk without assistance
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Freedom from target lesion revascularization (TLR) at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Freedom from target lesion revascularization (TLR) at 3 years
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Clinical success at 3 years
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: type II muscle fibre hypertrophy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Positive response to furosemid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall probability of survival at two years
Endpoint domain: Mortality/survival
Primary endpoint: Rate of disease-free survival at two years
Endpoint domain: Mortality/survival
Primary endpoint: Cumulative incidence of acute graft-versus-host disease at 100 days
Endpoint domain: Adverse events/effects
Primary endpoint: exercise-induced dyspnea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: survivorship free of revision for mechanical failure
Endpoint domain: Mortality/survival
Primary endpoint: Residual limb quadriceps muscle strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Rate of improvement in withdrawal severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total duration of withdrawal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: interval to local recurrence
Endpoint domain: Mortality/survival
Primary endpoint: behavioral control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean pain scores after surgery
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Time for epidural needle placement to achieve loss of resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time taken to mark the skin overlying the targeted epidural space
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean horizontal width of alveolar crest
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Variceal recurrence requiring further treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of treatment for congestive heart failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Safety of treatment (drop-out rate)
Endpoint domain: Adverse events/effects
Primary endpoint: First occurrence of myocardial infarction (MI)
Endpoint domain: Mortality/survival
Primary endpoint: First occurrence of any diabetes-related endpoint
Endpoint domain: Mortality/survival
Primary endpoint: Modified Rankin Scale score at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Control of HIV viremia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Caregiver depression scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Caregiver anxiety scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Responsiveness of SES-CD to changes in endoscopic disease activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: storage symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 12-month incidence of depressive and anxiety disorders
Endpoint domain: Mortality/survival
Primary endpoint: Prevalence of illicit drug use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NIH-CPSI total score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality-of-life impact score improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: VAS-2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS-3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HIV-associated risk behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Blood Pressure Normalization Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Panic attacks during carbon dioxide inhalation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective anxiety levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 99mTc‐DTPA clearance rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: care quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Aerobic peak capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in IOP (Intraocular Pressure)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of drug-related adverse experiences
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of discontinuations due to drug-related adverse experiences
Endpoint domain: Adverse events/effects
Primary endpoint: VAS-PtGlobal
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: VAS-pain
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: TT exchange rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Post-extubation stridor
Endpoint domain: Adverse events/effects
Primary endpoint: near complete response (nCR) rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: current psychological distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: nHF treatment failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Spherical refraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in oxygenation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: maximal strength values for knee extensors and elbow flexors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Latency to the first MSE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pulmonary Resistance (PR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: VEGF concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fluid overload values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GST enzyme activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sudden cardiac deaths
Endpoint domain: Mortality/survival
Primary endpoint: Nonsudden cardiac deaths
Endpoint domain: Mortality/survival
Primary endpoint: Plasma concentration of CBZ and CBZ-E
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptomatic status after CRT implantation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle power (extensor and flexor)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes